Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

Swiss pharma giant Roche today reported mixed results from late-stage trials for its experimental drug astegolimab, which is ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksTh ...

The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing the compound vs. placebo on ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...